Dr. Badarinath is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Shircliff Way
Ste 800
Jacksonville, FL 32204Phone+1 904-388-2619Fax+1 904-388-0240
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 2000- Emory University School of MedicineResidency, Internal Medicine, 1994 - 1997
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1994
Certifications & Licensure
FL State Medical License 2000 - 2025
GA State Medical License 1996 - 2001- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
- Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
- Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Publications & Presentations
PubMed
- 57 citationsPhase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil, Bryan Bienvenu, W. Graydon Harker
Clinical Colorectal Cancer. 2012-06-01 - 2 citationsPhase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancerHelen K. Chew, Lee S. Schwartzberg, Suprith Badarinath, Peter Rubin, Grace Shumaker
Springerplus. 2014-02-22 - 12 citationsA phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.James R. Berenson, Robert F. Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre
American Journal of Hematology. 2017-05-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
